Impact of the 2013 national rollout of CMS competitive bidding program: The disruption continues

Gary A. Puckrein, Irl B. Hirsch, Christopher G. Parkin, Bruce T. Taylor, Liou Xu, David Marrero

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

OBJECTIVE: Use of glucose monitoring is essentialtothe safety ofindividuals with insulin-treated diabetes. In 2011, the Centers for Medicare and Medicaid Services (CMS) implemented the Medicare Competitive Bidding Program (CBP) in nine test markets. This resulted in a substantial disruption of beneficiary access to self-monitoring of blood glucose (SMBG) supplies and significant increases in the percentage of beneficiaries with either reduced or no acquisition of supplies. These reductions were significantly associated with increased mortality, hospitalizations, and costs. The CBP was implemented nationally in July 2013. We evaluated the impact ofthis rollout to determine if the adverse outcomes seen in 2011 persisted. RESEARCH DESIGN AND METHODS: This longitudinal study followed 529,627 insulin-treated beneficiaries from 2009 through 2013 to assess changes in beneficiary acquisition of testing supplies in the initial nine test markets (TEST, n = 43,939) and beneficiaries not affected bythe 2011 rollout (NONTEST, n = 485,688). All Medicare beneficiary records for analysis were obtained from CMS. RESULTS: The percentages of beneficiaries with partial/no SMBG acquisition were significantly higher in both the TEST (37.4%) and NONTEST (37.6%) groups after the first 6 months of the national CBP rollout, showing increasesof 48.1% and 60.0%, respectively (both P < 0.0001). The percentage of beneficiaries with no record for SMBG acquisition increased from 54.1% in January 2013 to 62.5% by December 2013. CONCLUSIONS: Disruption of beneficiary access to their prescribed SMBG supplies has persisted and worsened. Diabetes testing supplies should be excluded from the CBP until transparent, science-based methodologies for safety monitoring are adopted and implemented.

Original languageEnglish (US)
Pages (from-to)949-955
Number of pages7
JournalDiabetes Care
Volume41
Issue number5
DOIs
StatePublished - May 1 2018
Externally publishedYes

Fingerprint

Competitive Bidding
Blood Glucose Self-Monitoring
Centers for Medicare and Medicaid Services (U.S.)
Medicare
Insulin
Safety
Longitudinal Studies
Hospitalization
Research Design
Costs and Cost Analysis
Glucose
Mortality

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Impact of the 2013 national rollout of CMS competitive bidding program : The disruption continues. / Puckrein, Gary A.; Hirsch, Irl B.; Parkin, Christopher G.; Taylor, Bruce T.; Xu, Liou; Marrero, David.

In: Diabetes Care, Vol. 41, No. 5, 01.05.2018, p. 949-955.

Research output: Contribution to journalArticle

Puckrein, Gary A. ; Hirsch, Irl B. ; Parkin, Christopher G. ; Taylor, Bruce T. ; Xu, Liou ; Marrero, David. / Impact of the 2013 national rollout of CMS competitive bidding program : The disruption continues. In: Diabetes Care. 2018 ; Vol. 41, No. 5. pp. 949-955.
@article{03a6d2301b174a67815d34eef9bfe838,
title = "Impact of the 2013 national rollout of CMS competitive bidding program: The disruption continues",
abstract = "OBJECTIVE: Use of glucose monitoring is essentialtothe safety ofindividuals with insulin-treated diabetes. In 2011, the Centers for Medicare and Medicaid Services (CMS) implemented the Medicare Competitive Bidding Program (CBP) in nine test markets. This resulted in a substantial disruption of beneficiary access to self-monitoring of blood glucose (SMBG) supplies and significant increases in the percentage of beneficiaries with either reduced or no acquisition of supplies. These reductions were significantly associated with increased mortality, hospitalizations, and costs. The CBP was implemented nationally in July 2013. We evaluated the impact ofthis rollout to determine if the adverse outcomes seen in 2011 persisted. RESEARCH DESIGN AND METHODS: This longitudinal study followed 529,627 insulin-treated beneficiaries from 2009 through 2013 to assess changes in beneficiary acquisition of testing supplies in the initial nine test markets (TEST, n = 43,939) and beneficiaries not affected bythe 2011 rollout (NONTEST, n = 485,688). All Medicare beneficiary records for analysis were obtained from CMS. RESULTS: The percentages of beneficiaries with partial/no SMBG acquisition were significantly higher in both the TEST (37.4{\%}) and NONTEST (37.6{\%}) groups after the first 6 months of the national CBP rollout, showing increasesof 48.1{\%} and 60.0{\%}, respectively (both P < 0.0001). The percentage of beneficiaries with no record for SMBG acquisition increased from 54.1{\%} in January 2013 to 62.5{\%} by December 2013. CONCLUSIONS: Disruption of beneficiary access to their prescribed SMBG supplies has persisted and worsened. Diabetes testing supplies should be excluded from the CBP until transparent, science-based methodologies for safety monitoring are adopted and implemented.",
author = "Puckrein, {Gary A.} and Hirsch, {Irl B.} and Parkin, {Christopher G.} and Taylor, {Bruce T.} and Liou Xu and David Marrero",
year = "2018",
month = "5",
day = "1",
doi = "10.2337/dc17-0960/-/DC1",
language = "English (US)",
volume = "41",
pages = "949--955",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "5",

}

TY - JOUR

T1 - Impact of the 2013 national rollout of CMS competitive bidding program

T2 - The disruption continues

AU - Puckrein, Gary A.

AU - Hirsch, Irl B.

AU - Parkin, Christopher G.

AU - Taylor, Bruce T.

AU - Xu, Liou

AU - Marrero, David

PY - 2018/5/1

Y1 - 2018/5/1

N2 - OBJECTIVE: Use of glucose monitoring is essentialtothe safety ofindividuals with insulin-treated diabetes. In 2011, the Centers for Medicare and Medicaid Services (CMS) implemented the Medicare Competitive Bidding Program (CBP) in nine test markets. This resulted in a substantial disruption of beneficiary access to self-monitoring of blood glucose (SMBG) supplies and significant increases in the percentage of beneficiaries with either reduced or no acquisition of supplies. These reductions were significantly associated with increased mortality, hospitalizations, and costs. The CBP was implemented nationally in July 2013. We evaluated the impact ofthis rollout to determine if the adverse outcomes seen in 2011 persisted. RESEARCH DESIGN AND METHODS: This longitudinal study followed 529,627 insulin-treated beneficiaries from 2009 through 2013 to assess changes in beneficiary acquisition of testing supplies in the initial nine test markets (TEST, n = 43,939) and beneficiaries not affected bythe 2011 rollout (NONTEST, n = 485,688). All Medicare beneficiary records for analysis were obtained from CMS. RESULTS: The percentages of beneficiaries with partial/no SMBG acquisition were significantly higher in both the TEST (37.4%) and NONTEST (37.6%) groups after the first 6 months of the national CBP rollout, showing increasesof 48.1% and 60.0%, respectively (both P < 0.0001). The percentage of beneficiaries with no record for SMBG acquisition increased from 54.1% in January 2013 to 62.5% by December 2013. CONCLUSIONS: Disruption of beneficiary access to their prescribed SMBG supplies has persisted and worsened. Diabetes testing supplies should be excluded from the CBP until transparent, science-based methodologies for safety monitoring are adopted and implemented.

AB - OBJECTIVE: Use of glucose monitoring is essentialtothe safety ofindividuals with insulin-treated diabetes. In 2011, the Centers for Medicare and Medicaid Services (CMS) implemented the Medicare Competitive Bidding Program (CBP) in nine test markets. This resulted in a substantial disruption of beneficiary access to self-monitoring of blood glucose (SMBG) supplies and significant increases in the percentage of beneficiaries with either reduced or no acquisition of supplies. These reductions were significantly associated with increased mortality, hospitalizations, and costs. The CBP was implemented nationally in July 2013. We evaluated the impact ofthis rollout to determine if the adverse outcomes seen in 2011 persisted. RESEARCH DESIGN AND METHODS: This longitudinal study followed 529,627 insulin-treated beneficiaries from 2009 through 2013 to assess changes in beneficiary acquisition of testing supplies in the initial nine test markets (TEST, n = 43,939) and beneficiaries not affected bythe 2011 rollout (NONTEST, n = 485,688). All Medicare beneficiary records for analysis were obtained from CMS. RESULTS: The percentages of beneficiaries with partial/no SMBG acquisition were significantly higher in both the TEST (37.4%) and NONTEST (37.6%) groups after the first 6 months of the national CBP rollout, showing increasesof 48.1% and 60.0%, respectively (both P < 0.0001). The percentage of beneficiaries with no record for SMBG acquisition increased from 54.1% in January 2013 to 62.5% by December 2013. CONCLUSIONS: Disruption of beneficiary access to their prescribed SMBG supplies has persisted and worsened. Diabetes testing supplies should be excluded from the CBP until transparent, science-based methodologies for safety monitoring are adopted and implemented.

UR - http://www.scopus.com/inward/record.url?scp=85046119939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046119939&partnerID=8YFLogxK

U2 - 10.2337/dc17-0960/-/DC1

DO - 10.2337/dc17-0960/-/DC1

M3 - Article

C2 - 29150529

AN - SCOPUS:85046119939

VL - 41

SP - 949

EP - 955

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 5

ER -